Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock suffered a major decline of -10.5% on 12/2/19. The shares closed at $3.16. Moreover, exceptionally high trading volume at 214% of normal accompanied the decline. The stock has declined -22.4% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
LXRX’s future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to be a major Value Eraser.
LXRX is currently unrated.
The stock is currently unrated.